Tamoxifen-loaded folate-conjugate poly[(p-nitrophenyl acrylate)-co-(N- isopropylacrylamide)] sub-microgel as antitumoral drug delivery system

Journal of Biomedical Materials Research - Part A

Volumn 95, Issue 4, 2010, Pages 1028-1040

  Blanco, M Dolores ^a   Guerrero, Sandra ^a   Benito, Marta ^a   Teijón, César ^a   Olmo, Rosa ^a   Muñíz, Enriqueta ^a   Katime, Issa ^b   Teijón, José M ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

culture cells; drug delivery; folate conjugate sub microgel; pharmacokinetic; tamoxifen

Indexed keywords

ADIPOCYTES; ANTITUMORAL DRUGS; CELL TYPES; CELL UPTAKE; CULTURE CELLS; FOLATE RECEPTOR; HELA CELL; IN-VITRO; MEAN RESIDENCE TIME; MICROGEL; N-ISOPROPYLACRYLAMIDES; PHARMACOKINETIC STUDIES; TAMOXIFEN; WISTAR RAT;

ACRYLIC MONOMERS; AMIDES; DERIVATIVES; DRUG DELIVERY; DRUG PRODUCTS; GELS; PHARMACOKINETICS;

CELL CULTURE;

4 NITROPHENYLACRYLATE N ISOPROPYLACRYLAMIDE COPOLYMER; COPOLYMER; FOLATE RECEPTOR; FOLIC ACID; FOLIC ACID CONJUGATE SUBMICROGEL; TAMOXIFEN; UNCLASSIFIED DRUG;

ADIPOCYTE; ANIMAL EXPERIMENT; ARTICLE; CELL TYPE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG UPTAKE; FEMALE; GEL; HUMAN; HUMAN CELL; INJECTION SITE; MEAN RESIDENCE TIME; NONHUMAN; RAT;

ACRYLIC RESINS; ANIMALS; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; FEMALE; FOLIC ACID; FREEZE DRYING; GELS; HUMANS; INJECTIONS, SUBCUTANEOUS; MATERIALS TESTING; MICROSCOPY, ELECTRON, SCANNING; NEOPLASMS; RATS; RATS, WISTAR; TAMOXIFEN;

EID: 78449305147     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.32929     Document Type: Article

References (44)

1. Moses MA, Brem H, Langer R,. Advancing the field of drug delivery: Taking aim at cancer. Cancer Cell 2003; 4: 337-341.
2. Prokop A, Davidson JM,. Nanovehicular intracellular delivery systems. J Pharm Sci 2008; 97: 3518-3590.
3. Moghimi SM, Hunter AC, Murray JC,. Nanomedicine: Current status and future prospects. FASEB J 2005; 19: 311-330.
4. Ferrari M,. Cancer nanotechnology: Opportunities and challenges. Nat Rev Cancer 2005; 5: 161-171.
5. Jabr-Milane LS, van Vlerken LE, Yadav S, Amiji MM,. Multi-functional nanocarriers to overcome tumor drug resistance. Cancer Treatment Rev 2008; 34: 592-602.
6. Blanco MD, Olmo R, Teijón JM,. Hydrogels. In:, Swarbrick J, Boylan JC, editors. Encyclopedia of Pharmaceutical Technology. New York: Marcel Dekker, Inc.; 2002. p 1-25.
7. Guerrero-Ramírez LG, Nuño-Donlucas SM, Cesteros LC, Katime I,. Samart copolymeric nanohydrogels: Synthesis, characterization and properties. Mat Chem Phys 2008; 112: 1088-1092.
8. Pérez-Álvarez L, Śez-Martínez V, Herńez E, Katime I,. Synthesis and characterization of pH-sensitive microgels by derivatization of npa-based reactive copolymers. Mat Chem Phys 2008; 112: 516-524.
9. Alexis F, Rhee JW, Richie JP, Radovic-Moreno AF, Langer R, Farokhzad OC,. New frontiers in nanotechnology for cancer treatment. Urol Oncol Sem Orig Invest 2008; 26: 74-85.
10. Ross JF, Chaudhuri PK, Ratnam M,. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer 1994; 73: 2432-2443.
11. Aronov O, Horowitz AT, Gabizon A, Gibson D,. Folate-targeted PEG as a potential carrier for carboplatin analogs. Synthesis and in vitro studies. Bioconjugate Chem 2003; 14: 563-574.
12. Shmeeda H, Mak L, Tzemach D, Astrahan P, Tarshish M, Gabizon A,. Intracellular uptake and intracavitary targeting of folate-conjugated liposomes in a mouse lymphoma model with up-regulated folate receptors. Mol Cancer Ther 2006; 5: 818-824.
13. Pérez-Álvarez L, Śez-Martínez V, Herńez E, Katime I,. Specific pH-responsive folate-conjugate microgels designed for antitumor therapy. Macromol Chem Phys 2009; 210: 467-477.
14. O'Regan RM, Jordan VC,. The evolution of tamoxifen therapy in breast cancer: Selective oestrogen-receptor modulators and downregulators. Lancet Oncol 2002; 3: 207-214.
15. Bonneterre J, Thurlimann B, Robertson JFR, Krzakowski M, Mauriac L, Koralewski P, Vergote I, Webster A, Steinberg M, von Euler M,. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the tamoxifen or arimidex randomized group efficacy and tolerability study. J Clin Oncol 2000; 18: 3748-3757.
16. de Lima GR, Facina G, Shida JY, Chein MBC, Tanaka P, Dardes RC, Jordan VC, Gebrim LH,. Effects of low dose tamoxifen on normal breast tissue from premenopausal women. Eur J Cancer 2003; 39: 891-898.
17. MacCallum J, Cummings J, Dixon JM, Miller WR,. Solid-phase extraction and high-performance liquid chromatographic determination of tamoxifen and its major metabolites in plasma. J Chromatogr B 1996; 678: 317-323.
18. Lee KH, Ward BA, Desta Z, Flockhart DA, Jones DR,. Quantification of tamoxifen and three metabolites in plasma by high-performance liquid chromatography with fluorescence detection: Application to a clinical trial. J Chromatogr B 2003; 791: 245-253.
19. Hu FX, Neoh KG, Kang ET,. Synthesis and in vitro anti-cancer evaluation of tamoxifen-loaded magnetite/PLLA composite nanoparticles. Biomaterials 2006; 27: 5725-5733.
20. Shah VP, Midha KK, Dighe S, McGilveray IJ, Skelly JP, Yacobi A, Layloff T, Viswanathan CT, Cook CE, McDowall RD, Pittman KA, Spector S,. Analytical methods validation: Bioavailability, bioequivalence, and pharmacokinetic studies. J Pharm Sci 1992; 81: 309-312.
21. Han X,. 9-NC-loaded folate-conjugated polymer micelles as tumor targeted drug delivery system: Preparation and evaluation in vitro. Int J Pharm 2009; 372: 125-131.
22. Doménech J, Martínez J, Pĺ JM,. Biofarmacia y Farmacocinética. Volumen I Farmacocinética. Madrid. Editorial Síntesis: Editorial Síntesis; 1997.
23. Humason GL,. Animal Tissue Techniques, 4th ed. New York: W. H. Freeman; 1979.
24. Shang Y, Brown M,. Molecular determinants for the tissue specificity of SERMs. Science 2002; 295: 2465-2468.
25. Chawla JS, Amiji MM,. Biodegradable poly(epsilon - caprolactone) nanoparticles for tumor-targeted delivery of tamoxifen. Int J Pharm 2002; 249: 127-138.
26. Gundimeda U,. Tamoxifen modulates protein kinase C via oxidative stress in estrogen receptor-negative breast cancer cells. J Biol Chem 1996; 271: 13504-13514.
27. Duh JL, Yu R, Jiao JJ, Matwyshyn GA, Li W, Tan TH, Kong ANT,. Activation of signal transduction kinases by tamoxifen. Pharm Res 1997; 14: 186-189.
28. Panyama J, Sahoo SK, Prabha S, Bargar T, Labhasetwar V,. Fluorescence and electron microscopy probes for cellular and tissue uptake of poly(D, L -lactide-co-glycolide) nanoparticles. Int J Pharm 2003; 262: 1-11.
29. Davda J, Labhasetwar V,. Characterization of nanoparticle uptake by endothelial cells. Int J Pharm 2002; 233: 51-59.
30. Sonvico F, Mornet S, Vasseur V, Dubernet C, Jaillard D, Degrouard J, Hoebeke J, Duguet E, Colombo P, Couvreur P,. Folate-conjugate iron oxide nanoparticles for solid tumor targeting as potential specific magnetic hyperthermia mediators: Synthesis, physicochemical characterization, and in vitro experiments. Bioconjugate Chem 2005; 16: 1181-1188.
31. Kelly KMM, Rowan BG, Ratnam M,. Modulation of the folate receptor α gene by estrogen receptor: Mechanism and implications in tumor targeting. Cancer Res 2003; 63: 2820-2828.
32. Lee ES, Na K, Bae YH,. Polymeric micelle for tumor pH and folate-mediated targeting. J Control Release 2003; 91: 103-113.
33. Shin SC, Choi JS, Li X,. Enhanced bioavailability of tamoxifen after oral administration of tamoxifen with quercetin in rats. Int J Pharm 2006; 313: 144-149.
34. Kisanga ER, Gjerde J, SchÃ̧tt Mellgren G, Lien EA,. Tamoxifen administration and metabolism in nude mice and nude rats. J Steroid Biochem Mol Biol 2003; 84: 361-367.
35. DeGregorio MW, Coronado E, Osborne CK,. Tumor and serum tamoxifen concentrations in the athymic nude mice. Cancer Chemother Pharmacol 1989; 23: 68-70.
36. Robinson SP, Langa-Fahey SM, Jordan VC,. Implications of tamoxifen metabolism in the athymic mouse for the study of antitumor effects upon human breast cancer xenografts. Eur J Cancer Clin Oncol 1989; 25: 1769-1776.
37. Boocock DJ, Brown K, Gibbs AH, Sanchez E, Turteltaub KW, White INH,. Identification of CYP forms involved in the activation of tamoxifen and irreversible binding to DNA. Carcinogenesis 2002; 23: 1897-1901.
38. Wegman P, Vainikka L, StÃl O, NordenskjÃld B, Skoog L, Rutqvist LE, Wingren S,. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res 2005; 7: R282-R290.
39. Crommentuny KML, Schellens JHM, van der Berg JD, Beijnen JH,. In-vitro metabolism of anti-cancer drugs, methods and applications: Paclitaxel, docetaxel, tamoxifen and ifosfamide. Cancer Treat Rev 1998; 24: 345-366.
40. Lien EA, Solheim E, Ueland PM,. Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Res 1991; 51: 4837-4844.
41. Mandlekar S, Hebbar V, Christov K, Kong ANT,. Pharmacodynamics of tamoxifen and its 4-hydroxy and N-desmethyl metabolites: Activation of caspases and induction of apoptosis in rat mammary tumors and in human breast cancer cell lines. Cancer Res 2000; 60: 6601-6606.
42. Reddy LH, Vivek K, Bakshi N, Murthy RSR,. Tamoxifen citrate loaded solid lipid nanoparticles (SLNâ.,): Preparation, characterization, in vitro drug release, and pharmacokinetic evaluation. Pharm Develop Tech 2006; 11: 167-177.
43. Ratner BD,. Reducing capsular thickness and enhancing angiogenesis around implant drug release systems. J Control Release 2002; 78: 211-218.
44. Sastre RL, Olmo R, Teijón C, Muñíz E, Teijón JM, Blanco MD,. 5-Fluorouracil plasma levels and biodegradation of subcutaneously injected drug-loaded microspheres prepared by spray-drying poly(D - L -lactide) and poly (D, L -lactide-co-glycolide) polymers. Int J Pharm 2007; 338: 180-190.